2
Participants
Start Date
January 1, 2021
Primary Completion Date
October 1, 2022
Study Completion Date
October 1, 2022
Blinatumomab
"Blinatumomab will be given as a 28-day continuous infusion with 14-days in between Cycle 1 and Cycle 2 as per the package insert and FDA approved labeling.~Patient weight greater than or equal to 45kg will receive 28 mcg/day~Patient weight less than 45kg will receive 15 mcg/m2/day"
Medical College of Wisconsin, Milwaukee
Collaborators (1)
Amgen
INDUSTRY
Michael Burke
OTHER